Protagonist Therapeutics (PTGX) Share-based Compensation (2015 - 2026)

Protagonist Therapeutics has disclosed Share-based Compensation across 12 years of filings, most recently posting $14.5 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $14.5 million, up 5.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $46.7 million (up 11.16% YoY), and the FY2025 annual result was $46.0 million, up 22.42% from the prior year.
• Share-based Compensation came in at $14.5 million for Q1 2026 at Protagonist Therapeutics, up from $10.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $14.5 million in Q1 2026 to a low of $5.5 million in Q4 2022.
• The 5-year median for Share-based Compensation is $8.9 million (2024), against an average of $8.9 million.
• Across the five-year window, Share-based Compensation surged 123.12% in 2022 and gained 3.88% in 2025, its largest moves.
• Protagonist Therapeutics' Share-based Compensation stood at $5.5 million in 2022, then rose by 19.76% to $6.6 million in 2023, then surged by 37.75% to $9.1 million in 2024, then rose by 17.68% to $10.7 million in 2025, then jumped by 35.68% to $14.5 million in 2026.
• The last three Share-based Compensation figures came in at $14.5 million (Q1 2026), $10.7 million (Q4 2025), and $10.6 million (Q3 2025), per Business Quant data.